At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision, its diseases and to develop new therapies for vision loss. 

The institute is constituted as a foundation. IOB started operations in 2018. 

At IOB, we accelerate the conversion of basic research into innovative treatments which change the field of ophthalmic therapy. Interdisciplinary teams of researchers and clinicians work hand in hand. These problem-solvers and innovators have in-depth knowledge of unmet medical needs, and daily exposure to patients. Together, they improve the understanding of vision, and of the cells involved in eye disease. In this highly collaborative environment, IOB turns discoveries and technologies into clinical benefits for patients with blinding conditions. We help advance the practice of ophthalmic disease based on the genetic, structural and functional understanding of the cell types and their interactions within the human eye.

At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of eye diseases and to develop new therapies for vision loss.

Therapeutics

Life Sciences

Health Care

Biotechnology

Medical Devices

Institute of Molecular and Clinical Ophthalmology Basel (IOB)

Botond Roska

Mukhtar Ullah

Michael Girard

Ji Hoon Han

Giuseppe Vaccaro

Alissa Muller

David Scott

Bence Gyorgy

Cameron Cowan

Research and Development

Institute of Molecular and Clinical Ophthalmology Basel (IOB)

Org chart

Teams

Research and Development

Similar companies